Clinical Trials Logo

Hay Fever clinical trials

View clinical trials related to Hay Fever.

Filter by:

NCT ID: NCT00305487 Completed - Clinical trials for Seasonal Allergic Rhinitis

Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)

Start date: March 2006
Phase: Phase 3
Study type: Interventional

The aim of the study is to determine the efficacy and safety of ciclesonide nasal spray in children with seasonal allergic rhinitis. Ciclesonide will be administered intranasally at two dose levels once daily. The study consists of a baseline period (1 to 3 weeks) and a treatment period (2 weeks).

NCT ID: NCT00261287 Completed - Clinical trials for Perennial Allergic Rhinitis

Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)

Start date: November 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of ciclesonide nasal spray for long term use in relieving symptoms in perennial allergic rhinitis.

NCT ID: NCT00247520 Active, not recruiting - Hay Fever Clinical Trials

Safety and Efficacy Study of rEV131 in Allergic Rhinitis

Start date: May 2005
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to see whether rEV131 when given as a nasal spray in a single dose to each nostril is safe and can reduce the signs and symptoms of allergic rhinitis (hay fever) caused by an allergen challenge. All patients enrolled will be known to be allergic to ragweed pollen and will be given ragweed pollen extract in both nostrils 30 minutes after either rEV131 or innactive vehicle (placebo). The signs and symptoms (sneezing, itching, stuffiness and runny nose) will each be given a score from 0 to 3 by the patient and these will be added together and the combined scores from patients treated with rEV131 will be compared with those who received placebo.

NCT ID: NCT00189917 Completed - Dermatitis, Atopic Clinical Trials

Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders

Start date: April 2004
Phase: Phase 1
Study type: Interventional

The purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in populations with atopic disorders.

NCT ID: NCT00163514 Completed - Allergic Rhinitis Clinical Trials

Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)

Start date: May 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo (inactive substance) nasal spray in relieving symptoms of perennial allergic rhinitis.

NCT ID: NCT00163501 Completed - Allergic Rhinitis Clinical Trials

Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)

Start date: December 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo (inactive substance) nasal spray in relieving symptoms of perennial allergic rhinitis.

NCT ID: NCT00163488 Completed - Allergic Rhinitis Clinical Trials

Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)

Start date: January 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of combined ciclesonide nasal spray administered along with a fixed combination of inhaled fluticasone dipropionate/salmeterol.

NCT ID: NCT00078195 Completed - Allergy Clinical Trials

Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies

Start date: April 2003
Phase: Phase 2
Study type: Interventional

A series of allergy shots may reduce symptoms of seasonal ragweed allergies. This study will determine whether taking a drug called omalizumab (also known as Xolair) before getting the allergy shots is more effective than allergy shots alone or other treatments, such as prescription antihistamines.